Literature DB >> 19521667

Successful thrombolytic therapy for acute kidney injury secondary to thrombosis of suprarenal inferior vena cava filter.

Azra Bihorac1, Craig S Kitchens.   

Abstract

Inferior vena cava (IVC) thrombosis is a complication that occurs in 1-32% of patients inserted with IVC filters (IVCF). Deployment of the filter in the suprarenal position is advocated in certain clinical conditions, and some reports suggest a higher incidence of renal complications in that position, especially among patients with malignancy. We report a case of acute kidney injury (AKI) due to acute thrombosis of a suprarenal IVCF, which was successfully treated with systemic thrombolytic therapy. We also provide a review of the literature in regard to the indications, complications, and outcomes of suprarenal IVCF. Suprarenal IVCF placement should be performed rarely, and then only after careful evaluation of the underlying renal function, and likely should be avoided in patients with malignancy and known hypercoagulable state. Systemic thrombolytic therapy is a feasible treatment option for acute thrombotic episodes of IVCF, assuming it is diagnosed early and there are no known contraindications.

Entities:  

Mesh:

Year:  2009        PMID: 19521667     DOI: 10.1007/s11239-009-0359-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  28 in total

1.  Inferior vena caval filters: review of a 26-year single-center clinical experience.

Authors:  C A Athanasoulis; J A Kaufman; E F Halpern; A C Waltman; S C Geller; C M Fan
Journal:  Radiology       Date:  2000-07       Impact factor: 11.105

2.  Long-term follow-up of percutaneous vena cava filters: a prospective study in 100 consecutive patients.

Authors:  J M Schleich; O Morla; M Laurent; B Langella; J Chaperon; C Almange
Journal:  Eur J Vasc Endovasc Surg       Date:  2001-05       Impact factor: 7.069

3.  Mechanical thrombectomy in inferior vena cava thrombosis after caval filter placement: a report of three cases.

Authors:  W L Poon; S H Luk; K Y Yam; Anselm C W Lee
Journal:  Cardiovasc Intervent Radiol       Date:  2002-05-20       Impact factor: 2.740

4.  Hyperfibrinogenolysis in disseminated adenocarcinoma.

Authors:  K Meijer; W M Smid; S Geerards; J van der Meer
Journal:  Blood Coagul Fibrinolysis       Date:  1998-04       Impact factor: 1.276

5.  Suprarenal inferior vena cava filter placement prior to transcatheter arterial embolization (TAE) of a renal cell carcinoma with large renal vein tumor thrombus: prevention of pulmonary tumor emboli after TAE.

Authors:  S Hirota; S Matsumoto; S Ichikawa; M Tomita; T Koshino; M Sako; M Kono
Journal:  Cardiovasc Intervent Radiol       Date:  1997 Mar-Apr       Impact factor: 2.740

6.  Perforation of the inferior vena cava with aortic and vertebral penetration by a suprarenal Greenfield filter.

Authors:  D Kim; D H Porter; J B Siegel; M Simon
Journal:  Radiology       Date:  1989-09       Impact factor: 11.105

7.  Suprarenal filter placement.

Authors:  L J Greenfield; M C Proctor
Journal:  J Vasc Surg       Date:  1998-09       Impact factor: 4.268

8.  Mechanical thrombectomy in patients with deep venous thrombosis.

Authors:  M Delomez; J P Beregi; S Willoteaux; J J Bauchart; B Janne d'Othée; P Asseman; N Perez; C Théry
Journal:  Cardiovasc Intervent Radiol       Date:  2001 Jan-Feb       Impact factor: 2.740

9.  Suprarenal inferior vena cava filters: a 20-year single-center experience.

Authors:  Sanjeeva P Kalva; Chrysanthi Chlapoutaki; Stephan Wicky; Alan J Greenfield; Arthur C Waltman; Christos A Athanasoulis
Journal:  J Vasc Interv Radiol       Date:  2008-05-27       Impact factor: 3.464

Review 10.  Postthrombotic syndrome in relation to vena cava filter placement: a systematic review.

Authors:  Mitchell A Fox; Susan R Kahn
Journal:  J Vasc Interv Radiol       Date:  2008-05-27       Impact factor: 3.464

View more
  1 in total

1.  Transcatheter thrombolytic therapy for symptomatic thrombo-occlusion of inferior vena cava filter.

Authors:  Liang Xiao; Jing Shen; Jia-Jie Tong; Zhe Zhang; Xiao-Lin Mu; Zheng-Jia Yi; Shuo Bai; Ke Xu
Journal:  Exp Ther Med       Date:  2012-11-30       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.